You are here: Home » PTI Stories » National » News
Business Standard

Reconsider restrictions on manufacturing of oxytocin in India: IMA to govt

Press Trust of India  |  New Delhi 

Stating the importance of life-saving drug for young mothers and obstetricians, the (IMA) has demanded a reconsideration of the government's policy which prohibits the import of the drug, and restricts its manufacture for domestic use.

The had exclusively handed over the production of to Karnataka Antibiotics and Pharmaceuticals Limited (KAPL) after reports of misuse of the drug in the dairy sector came to light.

The IMA has claimed that KAPL does not have the experience or the capacity to handle such a huge responsibility.

"As per the company's record, any bulk production would take over four years, which raises questions whether a single public sector company is competent enough to supply the needs of the entire nation.

"IMA would hold the government responsible for shortages in and unfortunate consequences," said R V Asokan, of IMA and a medical practitioner.

IMA has no objections to KAPL for oxytocin solely for veterinary purpose if indicated, but by curtailing the of a life-saving drug will only create an artificial bottleneck and shortage, said Santanu Sen, of IMA.

"It (oxytocin) is listed in the essential medicines list of WHO. Restricting its manufacture to one company, could jeopardise the lives of many young mothers by increasing the incidence of hemorrhages post-child birth, leading to subsequent morbidity and mortality," Sen said.

Oxytocin is also provided to pregnant women during and post-child birth to control bleeding.

accounts for 20 per cent of global maternal deaths with 56,000 casualties annually, the IMA said, adding that latest data suggests that (PPH) contributes around 22 per cent to the maternal mortality cases in

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Thu, February 14 2019. 00:35 IST